LEP and acute myeloid leukemia: To further validate Leptin as a predictor of relapse in patients with intermediate and advanced stage AML, the multivariate Cox model of the training cohort was fitted to the validation data, including an offset that was equal to the effect of Leptin in the model based on patients with acute leukaemia from the training cohort.